The Analyst Verdict: Editas Medicine In The Eyes Of 4 Experts
The Analyst Verdict: Editas Medicine In The Eyes Of 4 Experts
分析師的判決：4位專家眼中的Editas醫學
Across the recent three months, 4 analysts have shared their insights on Editas Medicine (NASDAQ:EDIT), expressing a variety of opinions spanning from bullish to bearish.
在最近三個月中，有4位分析師分享了他們的Editas Medicine（NASDAQ:EDIT）的見解，這些意見涵蓋了從看好到看淡的各種觀點。
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
下表提供了他們最近評級的精簡視圖，顯示了過去30天的不同情緒，並將其與前幾個月進行比較。
Analysts have set 12-month price targets for Editas Medicine, revealing an average target of $9.5, a high estimate of $15.00, and a low estimate of $7.00. Highlighting a 32.14% decrease, the current average has fallen from the previous average price target of $14.00.
分析師們爲Editas Medicine設定了12個月的價值目標，顯示出平均目標爲$9.5，高估價爲$15.00，低估價爲$7.00。當前平均值較前一個平均目標價值$14.00下降了32.14%。
Investigating Analyst Ratings: An Elaborate Study
分析師評級的調查：一項詳盡的研究
The standing of Editas Medicine...
通過對最近...
登入免費觀看全文
登入/註冊